The "Make America Healthy Again" commission is reviewing certain vaccines as some states push to restrict the use of COVID-19 ...
Data on mRNA vaccines sent by Moderna to European regulators before the COVID-19 outbreak included early tests of the mRNA ...
A member of the U.K. Parliament is calling for regulators to audit pharmaceutical companies that have made misleading ...
A trial of Moderna’s norovirus vaccine in the U.S. has been put on hold by the FDA over a reported case of neurological ...
Thousands of U.S. health agency employees were terminated and told it was for poor performance, though they'd received strong ...
MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...
EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...
Nanoparticle characterization is vital for mRNA vaccine efficacy, ensuring safety and regulatory compliance in the ...